MedTrace Logo

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

NCT03323658 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-01-10

Study results available
· View outcomes & findings →

Summary

This phase I trial studies the side effects and best dose of bexarotene in preventing breast cancer in patients at high risk for breast cancer. Bexarotene belongs to a class of drugs that are called rexinoids, and it may reduce the incidence of breast tumors.

Conditions

  • Breast Atypical Ductal Hyperplasia
  • Breast Atypical Lobular Hyperplasia
  • Breast Ductal Carcinoma In Situ
  • Breast Lobular Carcinoma In Situ
  • Invasive Breast Carcinoma

Interventions

DRUG

Bexarotene

Given topically

OTHER

Questionnaire Administration

Ancillary studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Parijatham (Priya) S Thomas · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-15
Primary Completion
2021-08-03
Completion
2022-03-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03323658 on ClinicalTrials.gov